NEW YORK (GenomeWeb) – At the annual meeting of the American Association for Cancer Research in Washington D.C. this week, representatives from Foundation Medicine presented new data on the company's adaptation of its comprehensive genomic profiling to predict tumor mutational burden and guide the use of immunotherapies.

The company also presented data offering new insights into specific molecular changes that appear to influence response to these increasingly popular drugs.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.